Navigation Links
PharmAthene Reports Third Quarter 2009 Financial and Operational Results
Date:11/12/2009

---------- ---------- ---------- ---------- Loss from operations (7,526,015) (3,971,526) (19,931,841) (30,473,015) Other income(expenses) Interest income 61,743 250,014 258,841 1,083,949 Interest expense (748,892) (628,470) (1,949,402) (1,947,245) Loss on early extinguishment of debt (4,690,049) - (4,690,049) - Change in fair value of derivative instruments (1,059,509) 7,604 (295,218) 123,148 ---------- ----- -------- ------- Total other income (expenses) (6,436,707) (370,852) (6,675,828) (740,148) ---------- -------- ---------- -------- Net loss (13,962,722) (4,342,378) (26,607,669) (31,213,163) Basic and diluted net loss per share $(0.50) $(0.20) $(0.97) $(1.41) Weighted average shares used in calculation of basic and diluted net loss per share 28,077,348 22,095,545 27,388,761 22,089,949

SOURCE PharmAthene, Inc.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today announced that its strategic partner VetStem ... dose confirmation study of AT-016, an adipose-derived allogeneic ... the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, ... it has received the second $1.0M tranche under ... Research (SBIR) grant valued at up to $3.0 ... aerosolized KL4 surfactant as a potential medical countermeasure ...  Discovery Labs was awarded an initial $1.0 million ...
(Date:7/29/2015)... , July 30, 2015 According to ... - Growth, Trends & Forecasts (2015-2020), , published by Mordor ... 30.25 billion by the end of 2020, with ... for more than 40% of the global market size. The ... a CAGR of 13.7% during the period of (2015-2020). ...
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... TDS Telecom's James Barr III, 65, is retiring as ... after 17 years in the role, the company said on Tuesday. ... recently president of TDS Telecom's local telecommunications operations, has been named ... next year. , ,Wittwer has been with the company for ...
... now you've had a chance to absorb all the news from ... presentations here -- click on DEMO 2006 in the "Watch ... always swirls around the conference comes from inquiring minds that want ... at least in part, is that I look at hundreds of ...
... said it has reached an agreement with Chiron Corp., ... patent lawsuit. , ,Third Wave said that no licenses or ... the agreement. , ,This leaves Third Wave with only one ... on appeal after a court awarded Third Wave damages. Stratagene ...
Cached Biology Technology:Why companies don't get invited to the DEMO conference 2Why companies don't get invited to the DEMO conference 3
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... but when it cracks or otherwise fails, it proves ... tend to be toughthey resist shatteringbut are also relatively ... ideal material, says Marios Demetriou, a senior research fellow ... advantage of being both strong and tougha combination called ...
... In the late 1950s, Richard Feynman famously imagined a ... by manipulating matter and creating structures all the way ... over fifty years after "There,s Plenty of Room at ... Angela Belcher, Donald Eigler, and Michael Roukes - are ...
... When most people in the developed world think ... dim memory of a vaccination at a pediatrician,s office. ... North America and much of Europe, researchers remain interested ... because improving the measles vaccine could help eliminate the ...
Cached Biology News:Caltech-led team creates damage-tolerant metallic glass 2Caltech-led team creates damage-tolerant metallic glass 3Caltech-led team creates damage-tolerant metallic glass 4Scaling up: The future of nanoscience 2Scaling up: The future of nanoscience 3Measles virus, a weapon against cancer? 2
Fingerprinting II comparative quantification and polymorphism analysis is an optional module that adds comparative quantification and polymorphism analysis functions to the Fingerprinting II Basic so...
... Ideal for hand-held applications or for ... II with a hand-held eight-port disposable manifold ... than a multi-channel pipette. The StatMatic II ... bottle sizes and can completely fill a ...
... The DNA Engine Tetrad thermal ... beyond the pioneering PTC-200 DNA Engine ... times the capacity with a footprint ... high throughput for laboratories that run ...
The PROTEAN II xi multi-cell 2-D conversion kit converts the PROTEAN II xi multi-cell to the PROTEAN II XL multi-cell for a wider format cell that accepts 17 to 18 cm IPG strips....
Biology Products: